The Immediate Access for the Terminally Ill Act accelerates patient access to experimental treatments, directly benefiting pharmaceutical and biotechnology companies developing late-stage therapies. This bill expands the market for investigational drugs, increasing revenue potential for companies with promising pipelines.
Impact: 6/10HR7104Congressional Bill